Download MendeleyIminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors.
McKittrick, B.A., Caldwell, J.P., Bara, T., Boykow, G., Chintala, M., Clader, J., Czarniecki, M., Courneya, B., Duffy, R., Fleming, L., Giessert, R., Greenlee, W.J., Heap, C., Hong, L., Huang, Y., Iserloh, U., Josien, H., Khan, T., Korfmacher, W., Liang, X., Mazzola, R., Mitra, S., Moore, K., Orth, P., Rajagopalan, M., Roy, S., Sakwa, S., Strickland, C., Vaccaro, H., Voigt, J., Wang, H., Wong, J., Zhang, R., Zych, A.(2015) Bioorg Med Chem Lett 25: 1592-1596
- PubMed: 25728416
- DOI: https://doi.org/10.1016/j.bmcl.2015.02.003
- Primary Citation of Related Structures:
4S1G, 4XX3, 4XX4 - PubMed Abstract:
The development of renin inhibitors with favorable oral pharmacokinetic profiles has been a longstanding challenge for the pharmaceutical industry. As part of our work to identify inhibitors of BACE1, we have previously developed iminopyrimidinones as a novel pharmacophore for aspartyl protease inhibition. In this letter we describe how we modified substitution around this pharmacophore to develop a potent, selective and orally active renin inhibitor.
Organizational Affiliation:
Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States. Electronic address: brian.mckittrick@merck.com.
